SLC5A2 and type 2 diabetes mellitus: Recent clinical trials have shown that the SGLT2 inhibitor dapagliflozin can reduce the cardiovascular death/hospitalization for heart failure (CV death/HHF) in patients with CHF, whether or not they have T2DM [10–12].